Lentigo Maligna – Comprehensive Medical Guide

Overview

Lentigo maligna (LM) is a slow‑growing, early form of melanoma that arises on chronically sun‑exposed skin, most often the face. It is considered the in‑situ (non‑invasive) stage of lentigo‑maligna melanoma (LMM). While LM itself does not penetrate deeper layers of the skin, if left untreated it can evolve into an invasive melanoma with a higher risk of metastasis.

Who it affects – LM predominantly occurs in people over age 50, with a marked predilection for individuals with fair skin (Fitzpatrick skin types I–III). Men are slightly more commonly diagnosed than women, likely because of occupational sun exposure patterns.

Prevalence – In the United States, LM accounts for approximately 4–7 % of all cutaneous melanomas, making it the most common melanoma subtype on the head and neck. The incidence rises with latitude; higher rates are reported in Australia, New Zealand, and Northern Europe where ultraviolet‑B (UV‑B) radiation is intense and cumulative lifetime sun exposure is greater ^[1][2].

Symptoms

Lentigo maligna may be subtle and often resembles benign pigmented lesions. The following signs should raise suspicion:

• Irregularly shaped brown or black macule – typically >5 mm in diameter, with fuzzy or ragged borders.
• Variegated color – mixture of light brown, dark brown, black, gray, or even tan.
• “Coffee‑bean” or “speckled” appearance – small, darker dots or globules scattered within the lesion.
• Uneven surface – mild elevation, scaling, or crusting may be present.
• Changes over time – enlargement, color shift, or new pigment within an existing freckle.
• Location – most often on the cheek, nose, forehead, ears, scalp, or the back of the hands.

Because LM can masquerade as a benign lentigo, solar lentigo, or seborrheic keratosis, any new or changing pigmented lesion on sun‑exposed skin warrants professional evaluation.

Causes and Risk Factors

Primary cause

Lentigo maligna is driven by DNA damage from long‑term ultraviolet radiation, especially UV‑B. The cumulative effect of chronic, intermittent sun exposure leads to mutations in the cKIT, NRAS, and BRAF genes that promote melanocyte proliferation in the epidermis.

Key risk factors

• Fair skin, red or blond hair, blue/green eyes – less melanin means less natural UV protection.
• Advanced age – DNA repair mechanisms decline with age.
• History of extensive sun exposure – outdoor occupations (farming, construction), recreational tanning, or living at high altitude.
• Prior non‑melanoma skin cancers – actinic keratoses, basal cell carcinoma, or squamous cell carcinoma indicate high cumulative UV damage.
• Immunosuppression – organ transplant recipients, HIV infection, or chronic immunosuppressive medication use.
• Genetic predisposition – familial melanoma syndromes (e.g., CDKN2A mutation) increase overall melanoma risk, though LM is less strongly linked.
• History of tanning bed use – artificial UV exposure adds to cumulative dose.

Diagnosis

Early detection relies on a thorough skin examination and, when indicated, dermoscopic or histopathologic evaluation.

Clinical examination

• Physician visual inspection using the ABCDE criteria (Asymmetry, Border, Color, Diameter, Evolution) plus the “E” for “evolution” specific to lentigo.
• Assessment of lesion location, size, and any surrounding field cancerization.

Dermatoscopy

Dermatoscopic patterns characteristic of LM include:

• Irregular pigmented network with “annular” or “asymmetrical” distribution.
• Granular pigmentation and dark dots (pepper‑type granules).
• Focal areas of regression (white scar‑like zones).

Dermatoscopy improves diagnostic accuracy up to 90 % when performed by an experienced clinician ^[3].

Biopsy

When LM is suspected, a skin biopsy is essential.

• Punch or shave biopsy – preferred for lesions ≤1 cm to obtain full epidermal thickness.
• Excisional biopsy – recommended for larger lesions or when invasive melanoma cannot be excluded.

Histopathology reveals atypical melanocytes confined to the epidermis, often with lentiginous (linear) proliferation along the basal layer, and “pagetoid” scatter of cells.

Additional tests (if invasive disease is suspected)

• Sentinel lymph node biopsy – reserved for confirmed invasive lentigo‑maligna melanoma.
• Imaging (CT, PET) – only if metastasis is clinically suspected.

Treatment Options

Because LM can be extensive on the face, treatment must balance complete removal with cosmetic outcomes.

Surgical excision

• Standard excision – 5‑mm clinical margins are typical, but many experts recommend 9‑mm or wider margins for facial LM to reduce recurrence.
• Mohs micrographic surgery – tissue‑sparing technique that examines 100 % of peripheral and deep margins intra‑operatively; recurrence rates < 5 % ^[4].
• Slow Mohs (staged excision) – similar to Mohs but tissue is processed with permanent sections for greater histologic detail.

Non‑surgical options

• Topical imiquimod 5 % – immune response modifier applied 5–7 days per week for 12–16 weeks. Cure rates of 70‑80 % reported in select series ^[5].
• Topical 5‑fluorouracil (5‑FU) – used less frequently; may cause significant irritation.
• Radiation therapy – useful for patients who cannot undergo surgery; hypofractionated regimens (e.g., 30 Gy in 5 fractions) provide local control in 85‑90 % of cases.
• Cryotherapy – limited to very small lesions; high recurrence when used alone.
• Photodynamic therapy (PDT) – emerging data suggest modest efficacy; still considered experimental.

Adjunctive measures

• Wound care and scar management (silicone gel sheets, moisturizers).
• Regular follow‑up dermoscopic mapping of the treatment field.

Lifestyle and self‑care

While not a direct treatment, sun‑avoidance and diligent skin monitoring help prevent new lesions and recurrence.

Living with Lentigo Maligna

Managing LM after treatment involves vigilance and skin‑friendly habits.

• Self‑skin exam – perform a thorough check every month; use mirrors or enlist a partner for hard‑to‑see areas.
• Dermatology follow‑up – schedule visits every 3–6 months for the first 2 years, then annually if no recurrence.
• Sunscreen routine – broad‑spectrum SPF 30+ applied 15 minutes before outdoor exposure, re‑applied every 2 hours.
• Protective clothing – wide‑brim hats, UV‑blocking sunglasses, and UPF clothing.
• Moisturize – keep treated areas hydrated to lessen scar formation.
• Psychosocial support – counseling or support groups can help cope with anxiety about recurrence.
• Document lesions – photograph or use a dermatoscopic imaging system for baseline comparison.

Prevention

Because LM is primarily a result of cumulative UV injury, primary prevention strategies are effective.

1. Daily sunscreen – use a water‑resistant, broad‑spectrum product with SPF 30 or higher; consider mineral formulations (zinc oxide/titanium dioxide) for sensitive skin.
2. Avoid midday sun – seek shade between 10 a.m. and 4 p.m. when UV intensity peaks.
3. Protective garments – long‑sleeved shirts, pants, and wide‑brim hats.
4. UV‑index monitoring – use apps or weather reports to plan outdoor activities.
5. Regular skin checks – annual full‑body exams by a dermatologist, especially after age 40.
6. Limit tanning beds – avoid artificial UV sources altogether.
7. Vitamin D balance – obtain vitamin D through diet or supplements rather than intentional sun exposure.

Complications

If left untreated, LM can progress to invasive lentigo‑maligna melanoma (LMM), which carries the following risks:

• Local invasion – tumor penetrates the dermis and can involve deeper structures (periorbital tissue, nasal cartilage).
• Metastasis – regional (lymph node) spread and, less commonly, distant metastasis to lungs, liver, brain.
• Higher mortality – invasive LMM on the head/neck has a 5‑year survival of 70‑80 % compared with >95 % for in‑situ LM when treated early.
• Cosmetic disfigurement – large or recurrent lesions may require extensive surgery, resulting in functional and aesthetic deficits.
• Psychological impact – fear of cancer recurrence can lead to anxiety, depression, or social withdrawal.

When to Seek Emergency Care

---

Sources:
[1] American Cancer Society. “Melanoma Skin Cancer.” 2023.
[2] WHO. “Skin Cancer – Global Statistics.” 2022.
[3] Cinotti E, et al. Dermoscopy of Lentigo Maligna. *J Am Acad Dermatol.* 2021.
[4] Karia PS, et al. Mohs Surgery for Lentigo Maligna: Outcomes. *Dermatol Surg.* 2020.
[5] Ferrara A, et al. Imiquimod for Lentigo Maligna: A Systematic Review. *J Dermatol Treat.* 2022.
All content is for educational purposes and does not replace professional medical advice.